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Controlled release (CR) dosage forms have been extensively used to improve therapy with several 
important drugs. However, the development processes are faced with several physiological difficulties 
such as the inability to restrain and localize the system within the desired region of the gastrointestinal 
tract and the highly variable nature of the gastric emptying process. This variability may lead to 
unpredictable bioavailability and times to achieve peak plasma levels. On the other hand, incorporation 
of the drug in a controlled release gastroretentive dosage forms (CR-GRDF) which can remain in the 
gastric region for several hours would significantly prolong the gastric residence time of drugs and 
improve bioavailability, reduce drug waste, and enhance the solubility of drugs that are less soluble in 
high pH environment. Gastroretention would also facilitate local drug delivery to the stomach and 
proximal small intestine. Thus, gastroretention could help to provide greater availability of new products 
and consequently improved therapeutic activity and substantial benefits to patients. Controlled gastric 
retention of solid dosage form may be achieved by the mechanisms of floatation, mucoadhesion, 
sedimentation, expansion or by a modified shaped system. The purpose of this paper is to review the 
recent literature and current technology used in the development of gastroretentive dosage forms.  
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INTRODUCTION 
Oral controlled release (CR) dosage forms 
(DFs) have been developed over the past 
three decades due to their considerable 
therapeutic advantages such as ease of 
administration, patient compliance and 
flexibility in formulation. However, this 
approach is bedilled with several physiological 
difficulties such as inability to restrain and 
locate the controlled drug delivery system 
within the desired region of the 
gastrointestinal tract (GIT) due to variable 
gastric emptying and motility. Furthermore, 
the relatively brief gastric emptying time (GET) 
in humans which normally averages 2-3 h 
through the major absorption zone, i.e., 
stomach and upper part of the intestine can 
result in incomplete drug release from the 
drug delivery system leading to reduced 
efficacy of the administered dose
1
. Therefore, 
control of placement of a drug delivery system 
(DDS) in a specific region of the GI tract offers 
advantages for a variety of important drugs 
characterized by a narrow absorption window 
in the GIT or drugs with a stability problem
2
. 
These considerations have led to the 
development of a unique oral controlled 
release dosage form with gastroretentive 
properties. After oral administration, such a 
DF would be retained in the stomach and 
release the drug there in a controlled and 
prolonged manner, so that the drug could be 
supplied continuously to its absorption sites in 
the upper gastrointestinal tract
3
. 
Gastroretentive dosage form can remain in 
the gastric region for several hours and hence 
significantly prolong the gastric residence time 
of drugs. Prolonged gastric retention improves 
bioavailability, reduces drug waste, and 
improves solubility of drugs that are less 
soluble in a high pH environment. It is also 
suitable for local drug delivery to the stomach 
and proximal small intestines
4
. 
Gastroretention helps to provide better 
availability of new products with suitable 
therapeutic activity and substantial benefits for 
patients. This mode of administration would 
best achieve the known pharmacokinetic and 
pharmacodynamic advantages of CR-DFs of 
these drugs.  
The need for gastroretentive dosage forms 
(GRDFs) has led to extensive efforts in both 
academia and industry towards the 
development of such drug delivery systems. 
These efforts resulted in GRDFs that were 
designed, in large part, based on the following 
approaches. 
(a) Low density form of the DF that causes 
buoyancy in gastric fluid
5
 
(b) High density DF that is retained in the 
bottom of the stomach
6
 
(c) Bioadhesion to stomach mucosa
7
 
(d) Slowed motility of the gastrointestinal tract 
by concomitant administration of drugs or    
      pharmaceutical excipients
8, 9
 
(e) Expansion by swelling or unfolding to a 
large size which limits emptying of the DF 
through the pyloric sphincter
10
.  
The current review deals with the 
gastroretentive approaches that has recently 
become leading methodologies in the field of 
controlled and site specific drug delivery 
system. 
 
SUITABLE DRUG CANDIDATES FOR 
GASTRORETENTION 
In general, appropriate candidates for CR-
GRDF are molecules that have poor colonic 
absorption but are characterized by better 
absorption properties at the upper parts of the 
GIT:  
• Narrow absorption window in GItract,  
e.g., riboflavin and levodopa 
• Primarily absorbed from stomach and 
upper part of GItract, e.g., calcium 
supplements, chlordiazepoxide and 
cinnarazine 
• Drugs that act locally in the stomach, e.g., 
antacids and misoprostol 
• Drugs that degrade in the colon, e.g., 
ranitidine HCl and metronidazole 
• Drugs that disturb normal colonic bacteria,  
e.g., amoxicillin trihydrate 
 
FACTORS CONTROLLING GASTRIC 
RETENTION OF DOSAGE FORMS 
The gastric retention time (GRT) of dosage 
forms is controlled by several factors such as 
density and size of the dosage form, food 
intake, nature of the food, posture, age, sex, 
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sleep and disease state of the individual (e.g., 
gastrointestinal diseases and diabetes) and 
administration of drugs such as prokinetic 
agents (cisapride and metoclopramide).  
1. Density of dosage form  
Dosage forms having a density lower than that 
of gastric fluid experience floating behavior 
and hence gastric retention. A density of <1.0 
gm/cm
3
 is required to exhibit floating property. 
However, the floating tendency of the dosage 
form usually decreases as a function of time, 
as the dosage form gets immersed into the 




2. Size of dosage form 
The size of the dosage form is another factor 
that influences gastric retention. The mean 
gastric residence times of non-floating dosage 
forms are highly variable and greatly 
dependent on their size, which may be small, 
medium, and large units.
 
In fed conditions, the 
smaller units get emptied from the stomach 
during the digestive phase and the larger units 
during the housekeeping waves. In most 
cases, the larger the size of the dosage form, 
the greater will be the gastric retention time
12
 
because the larger size would not allow the 
dosage form to quickly pass through the 
pyloric antrum into the intestine. Thus the size 
of the dosage form appears to be an important 
factor affecting gastric retention.  
3. Food intake and nature of food 
Food intake, the nature of the food, caloric 
content, and frequency of feeding have a 
profound effect on the gastric retention of 
dosage forms.
 
The presence or absence of 
food in the stomach influences the GRT of the 
dosage form. Usually, the presence of food 
increases the GRT of the dosage form
 
and 
increases drug absorption by allowing it to 
stay at the absorption site for a longer time. In 
a gamma scintigraphic study of a bilayer 





gastric residence time was 199 ± 69 minutes; 
after a light breakfast, a remarkable 
enhancement of average GRT to 618 ± 208 
minutes was observed. The above results are 




which show an increase in the relative 
heights of the floating units after meal 
consumption. 
4. Effect of gender, posture and age 
A study by Mojaverian et al
15
 found that 
females showed comparatively shorter mean 
ambulatory GRT than males, and the gastric 
emptying in women was slower than in men. 
The authors also studied the effect of posture 
on GRT, and found no significant difference in 
the mean GRT for individuals in upright, 
ambulatory and supine state. On the other 
hand, in a comparative study in humans by 
Gansbeke et al
16
, the floating and non-floating 
systems behaved differently. In the upright 
position, the floating systems floated to the top 
of the gastric contents and remained for a 
longer time, showing prolonged GRT. But the 
non-floating units settled to the lower part of 
the stomach and underwent faster emptying 
as a result of peristaltic contractions, and the 
floating units remained away from the pylorus. 
However, in supine position, the floating units 




TYPES OF GASTRORETENTIVE DOSAGE 
FORMS 
A. Floating drug delivery systems 
Floating drug delivery systems (FDDS) have a 
bulk density less than gastric fluids and so 
remain buoyant in the stomach without 
affecting gastric emptying rate for a prolonged 
period of time. While the system is floating on 
the gastric contents, the drug is released 
slowly at the desired rate from the system. 
After release of drug, the residual system is 
emptied from the stomach. This results in an 
increased GRT and a better control of the 
fluctuations in plasma drug concentration.  
FDDS can be divided into non-effervescent 
and gas-generating system 
(a) Non-effervescent systems 
This type of system, after swallowing, swells 
unrestrained via imbibition of gastric fluid to an 
extent that it prevents their exit from the 
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stomach. One of the formulation methods of 
such dosage forms involves the mixing of the 
drug with a gel, which swells in contact with 
gastric fluid after oral administration and 
maintains a relative integrity of shape and a 
bulk density of less than one within the outer 
gelatinous barrier
18
. The air trapped by the 
swollen polymer confers buoyancy to these 
dosage forms. Excipients used most 
commonly in these systems include 
hydroxypropyl methyl cellulose (HPMC), 
polyacrylate polymers, polyvinyl acetate, 
Carbopol, agar, sodium alginate, calcium 
chloride, polyethylene oxide and 
polycarbonates. 
This system can be further divided into four 
sub-types: 
(i) Colloidal gel barrier system 
Sheth and Tossounian first designated this 
‘hydrodynamically balanced system’
19
. Such a 
system contains drug with gel-forming 
hydrocolloids meant to remain buoyant on the 
stomach content. This prolongs GRT and 
maximizes the amount of drug that reaches its 
absorbtion sites in the solution form for ready 
absorption. This system incorporates a high 
level of one or more gel-forming highly soluble 
cellulose type hydrocolloid, e.g., 
hydroxypropyl cellulose, hydoxyethyl 
cellulose, hydroxypropyl methyl cellulose 
(HPMC), polysacharides and matrix-forming 
polymer such as polycarbophil, polyacrylate 
and polystyrene. On coming in contact with 
gastric fluid, the htdrocolloid in the system 
hydrates and forms a colloid gel barrier 
around its surface. 
(ii) Microporous compartment system 
This technology is based on the encapsulation 
of a drug reservoir inside a microporous 
compartment with pores along its top and 
bottom walls
20
. The peripheral walls of the 
drug reservoir compartment are completely 
sealed to prevent any direct contact of gastric 
surface with the undissolved drug. In the 
stomach, the floatation chamber containing 
entrapped air causes the delivery system to 
float over the gastric content. Gastric fluid 
enters through the aperture, dissolves the 
drug and carries the dissolved drug for 
continuous transport across the intestine for 
absorption. 
(iii) Alginate beads 
Multi-unit floating dosage forms have been 
developed from freeze-dried calcium 
alginate
21
. Spherical beads of approximately 
2.5 mm in diameter can be prepared by 
dropping sodium alginate solution into 
aqueous solution of calcium chloride, causing 
the precipitation of calcium alginate. The 
beads are then separated, snap-frozen in 
liquid nitrogen, and freeze-dried at -40ºC for 
24 hours, leading to the formation of a porous 
system, which can maintain a floating force for 
over 12 hours. These floating beads gave a 
prolonged residence time of more than 5.5 
hours.  
(iv) Hollow microspheres / Microballons 
Hollow microspheres loaded with drug in their 
outer polymer shelf were prepared by a novel 
emulsion solvent diffusion method
22
. The 
ethanol/dichloromethane solution of the drug 
and an enteric acrylic polymer was poured 
into an agitated solution of Poly Vinyl Alcohol 
(PVA) that was thermally controlled at 40ºC. 
The gas phase is generated in the dispersed 
polymer droplet by the evaporation of 
dichloromethane formed and internal cavity in 
the microsphere of the polymer with drug. The 
microballoon floated continuously over the 
surface of an acidic dissolution media 
containing surfactant for more than 12 h. 
(b) Gas-generating (Effervescent) systems 
These buoyant systems utilize matrices 
prepared with swellable polymers such as 
methocel, polysaccharides (e.g., chitosan), 
effervescent components (e.g., sodium 
bicarbonate, citric acid or tartaric acid)
23
. The 
system is so prepared that upon arrival in the 
stomach, carbon dioxide is released, causing 
the formulation to float in the stomach. Other 
approaches and materials that have been 
reported are a mixture of sodium alginate and 
sodium bicarbonate
24
, multiple unit floating 
pills that generate carbon dioxide when 
ingested, floating minicapsules with a core of 
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sodium bicarbonate, lactose and 
polyvinylpyrrolidone coated with 
hydroxypropyl methylcellulose (HPMC), and 
floating systems based on ion exchange resin 
technology, etc. 
B. Expandable systems 
Expandable gastroretentive dosage forms 
(GRDFs) have been designed over the past 3 
decades. They were originally created for 
possible veterinary use but later the design 
was modified for enhanced drug therapy in 
humans. These GRDFs are easily swallowed 
and reach a significantly larger size in the 
stomach due to swelling or unfolding 
processes that prolong their GRT. After drug 
release, their dimensions are minimized with 
subsequent evacuation from the stomach
25
. 
Gastroretentivity is enhanced by the 
combination of substantial dimensions with 
high rigidity of the dosage form to withstand 
the peristalsis and mechanical contractility of 
the stomach. Positive results were obtained in 
preclinical and clinical studies evaluating the 
GRT of expandable GRDFs. Narrow 
absorption window drugs compounded in such 
systems have improved in vivo absorption 
properties. 
C. Bio/Muco-adhesive systems 
Bioadhesive drug delivery systems (BDDS) 
are used as a delivery device within the 
lumen to enhance drug absorption in a site-
specific manner. This approach involves the 
use of bioadhesive polymers, which can 
adhere to the epithelial surface in the 
stomach
26
. Gastric mucoadhesion does not 
tend to be strong enough to impart to 
dosage forms the ability to resist the strong 
propulsion forces of the stomach wall. The 
continuous production of mucous by the 
gastric mucosa to replace the mucous that 
is lost through peristaltic contractions and 
the dilution of the stomach content also 
seem to limit the potential of mucoadhesion 
as a gastroretentive force. Some of the 
most promising excipients that have been 
used commonly in these systems include 
polycarbophil, carbopol, lectins, chitosan 
and gliadin, etc. 
D. High-density systems 
Sedimentation has been employed as a 
retention mechanism for pellets that are 
small enough to be retained in the rugae or 
folds of the stomach body near the pyloric 
region, which is the part of the organ with 
the lowest position in an upright posture. 
Dense pellets (approximately 3g/cm
-3
) 
trapped in rugae also tend to withstand the 
peristaltic movements of the stomach wall. 
With pellets, the GI transit time can be 
extended from an average of 5.8–25 hours, 
depending more on density than on the 
diameter of the pellets
27
. Commonly used 
excipients are barium sulphate, zinc oxide, 
titanium dioxide and iron powder, etc. 





ADVANTAGES OF GASTRORETENTIVE 
DRUG DELIVERY SYSTEMS 
Enhanced bioavailability 
The bioavailability of riboflavin CR-GRDF is 
significantly enhanced in comparison to the 
administration of non-GRDF CR polymeric 
formulations. There are several different 
processes, related to absorption and transit of 
the drug in the gastrointestinal tract, that act 




Enhanced first-pass biotransformation 
In a similar fashion to the increased efficacy of 
active transporters exhibiting capacity limited 
activity, the pre-systemic metabolism of the 
tested compound may be considerably 
increased when the drug is presented to the 
metabolic enzymes (cytochrome P450, in 
particular CYP3A4) in a sustained manner, 
rather than by a bolus input. 
Sustained drug delivery/reduced frequency 
of dosing 
For drugs with relatively short biological half-
life, sustained and slow input from CR-GRDF 
may result in a flip-flop pharmacokinetics and 
enable reduced dosing frequency. This 
feature is associated with improved patient 
compliance, and thereby improves therapy. 
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Targeted therapy for local ailments in the 
upper GIT 
The prolonged and sustained administration of 
the drug from GRDF to the stomach may be 
advantageous for local therapy in the stomach 
and small intestine. By this mode of 
administration, therapeutic drug 
concentrations may be attained locally while 
systemic concentrations, following drug 
absorption and distribution, are minimal. 
Reduced fluctuations of drug 
concentration 
Continuous input of the drug following CR-
GRDF administration produces blood drug 
concentrations within a narrower range 
compared to the immediate release dosage 
forms. Thus, fluctuations in drug effects are 
minimized and concentration dependent 
adverse effects that are associated with peak 
concentrations can be prevented. This feature 




Improved selectivity in receptor activation 
Minimization of fluctuations in drug 
concentration also makes it possible to obtain 
certain selectivity in the elicited 
pharmacological effect of drugs that activate 
different types of receptors at different 
concentrations. 
Reduced counter-activity of the body 
In many cases, the pharmacological response 
which intervenes with the natural physiologic 
processes provokes a rebound activity of the 
body that minimizes drug activity. Slow input 
of the drug into the body was shown to 
minimize the counter activity leading to higher 
drug efficiency. 
Extended time over critical (effective) 
concentration 
For certain drugs that have non-concentration 
dependent pharmacodynamics, such as beta-
lactam antibiotics, the clinical response is not 
associated with peak concentration, but rather 
with the duration of time over a critical 
therapeutic concentration. The sustained 
mode of administration enables extension of 
the time over a critical concentration and thus 
enhances the pharmacological effects and 
improves the clinical outcomes. 
Minimized adverse activity at the colon 
Retention of the drug in the GRDF at the 
stomach minimizes the amount of drug that 
reaches the colon. Thus, undesirable activities 
of the drug in colon may be prevented. This 
pharmacodynamic aspect provides the 
rationale for GRDF formulation for beta-lactam 
antibiotics that are absorbed only from the 
small intestine, and whose presence in the 
colon leads to the development of 
microorganism’s resistance. 
Site specific drug delivery  
A floating dosage form is a feasible 
approach especially for drugs which have 
limited absorption sites in upper small 
intestine
30
. The controlled, slow delivery of 
drug to the stomach provides sufficient local 
therapeutic levels and limits the systemic 
exposure to the drug. This reduces side 
effects that are caused by the drug in the 
blood circulation. In addition, the prolonged 
gastric availability from a site directed 
delivery system may also reduce the dosing 
frequency. 
 




 designed floatable gastro-
etentive tablet of metformin hydrochloride 
using a gas-generating agent and gel-forming 
hydrophilic polymer. The formulation was 
optimized on the basis of floating ability and in 
vitro drug release. The in vitro drug release 
test of these tablets indicated controlled 
sustained release of metformin hydrochloride 
and 96-99% released at the end of 8 h. 
Jaimini et al
32
 prepared floating tablets of 
famotidine employing two different grades of 
Methocel K100 (HPMC K100) and Methocel 
K15 (HPMC K15) by an effervescent 
technique. These grades were evaluated for 
their gel-forming properties. The tablets with 
Methocel K100 were found to float for a longer 
duration compared with the formulation 
containing Methocel K15M. Decrease in the 
Garg  & Gupta 
Trop J Pharm Res September 2008; 7 (3) 1061 
citric acid level increased the floating lag time. 
The drug release from the tablets was 
sufficiently sustained and non-Fickian 
transport of the drug from tablets was 
confirmed. 
       Table 1: Commonly used drugs in formulation of gastroretentive dosage forms 
 
S/No. Dosage form Drug 
1.  Floating 
microspheres  
Aspirin, griseofulvin, p-nitroaniline, ibuprofen, 
terfinadine and Tranilast  
2.  Floating granules  Diclofenac sodium, indomethacin and prednisolone  
3.  Films  Cinnarizine  
4.  Floating capsules  Chlordiazepoxide hydrogen chloride, diazepam, 
furosemide, misoprostol, L-dopa, benserazide, 
ursodeoxycholic acid and pepstatin  
5.  Floating tablets 
and pills  
Acetaminophen, acetylsalicylic acid, ampicillin, 
amoxycillin trihydrate, atenolol, diltiazem, 
fluorouracil, isosorbide mononitrate, p- 
aminobenzoic acid, theophylline and verapamil 
 
 
        Table 2: Gastroretentive products available in the market 
 
S/No. Brand name Active ingredient 
1 Cifran OD Ciprofloxacin 
2 Madopar Levodopa and benserazide 
3 Valrelease Diazepam 
4 Topalkan Aluminium-magnesium antacid 
5 Almagate Flatcoat Antacid 




Figure 1: Formulation of floating microspheres 
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Badve et al
33
 developed hollow calcium 
pectinate beads for floating-pulsatile release 
of diclofenac sodium intended for 
chronopharmacotherapy. Floating pulsatile 
concept was applied to increase the gastric 
residence of the dosage form having lag 
phase followed by a burst release. This 
approach suggested the use of hollow calcium 
pectinate microparticles as promising floating-
pulsatile drug delivery system for site- and 
time-specific release of drugs for 
chronotherapy of diseases. 
Chavanpatil et al
34
 developed a new 
gastroretentive sustained release delivery 
system of ofloxacin with floating, swellable 
and bioadhesive properties. Various release 
retarding polymers such as psyllium husk, 
HPMC K100M and a swelling agent, 
crosspovidone, in combinations were tried and 
optimized to obtain release profile over 24 h. 
The in vitro drug release followed Higuchi 
kinetics and the drug release mechanism was 
found to be non-Fickian. 
Rahman et al
35
 established a bilayer-floating 
tablet (BFT) for captopril using direct 
compression technology. HPMC K-grade and 
effervescent mixture of citric acid and sodium 
bicarbonate formed the floating layer. The 
release layer contained captopril and various 
polymers such as HPMC-K15M, PVP-K30 and 
Carbopol 934, alone or in combination with 
the drug. The formulation followed the Higuchi 
release model and showed no significant 
change in physical appearance, drug content, 
floatability or in vitro dissolution pattern after 
storage at 45 °C/75% RH for three months. 
Xiaoqiang et al
36
 developed a sustained 
release tablet for phenoporlamine 
hydrochloride because of its short biological 
half life. Three floating matrix tablets based on 
a gas-forming agent were prepared. HPMC 
K4M and Carbopol 971P were used in 
formulating the hydrogel system. Incorporation 
of sodium bicarbonate into the matrix resulted 
in the tablets floating over simulated gastric 
fluid for more than 6 hours. The dissolution 
profile of all the tablets showed non-Fickian 
diffusion in simulated gastric fluid.  
Sharma et al
37
 developed a multiparticulate 
floating pulsatile drug delivery system using 
porous calcium silicate and sodium alginate, 
for time- and site-specific drug release of 
meloxicam. Prepared beads were spherical 




 prepared microspheres with 
HPMC and ethyl cellulose using solvent 
evaporation method. The shape and surface 
morphology of the microspheres were 
characterized by optical and scanning electron 
microscopy. The microspheres exhibit 
prolonged drug release (8 h) and remained 
buoyant for more than 10 h. In vitro studies 
demonstrated diffusion-controlled drug 
release from the microspheres. 
Chavanpatil et al
39
 developed a 
gastroretentive dosage form for ofloxacin to 
be taken preferably once daily. The design of 
the delivery system based on a sustained 
release (SR) formulation with swelling and 
floating features in order to prolong gastric 
retention. Different polymers such as psyllium 
husk, HPMC K100M, crosspovidone and its 
combination were used and the  formulations 
were evaluated for buoyancy, stability, drug 
content and drug release studies.  
Jain et al
40
 designed a controlled release 
system to increase GRT without contact with 
gastric mucosa. The was achieved through 
the preparation of floating microspheres by 
emulsion solvent diffusion technique 
consisting of calcium silicate (FLR) as a 
porous carrier, repaglinide and a Eudragit 
polymer. The effect of various formulation and 
process variables were studied.  
Patel et al
41
 formulated and evaluated floating 
tablets of ranitidine. Two fillers, namely, Avicel 
PH 102 and Tablettose 80 were used. It was 
observed that viscosity had a major influence 
on drug release from hydrophilic matrices as 
well as floating properties. 
Muthusamy et al
42
 designed a sustained 
release floating micropellets of lansoprazole  
by emulsion solvent diffusion technique using 
drug to carrier ratios of 1:1, 1:2, 1:3. HPMC, 
methyl cellulose and chitosan were used as 
carriers. The yield of micropellets was up to 
82%. The drug to chitosan ratio of 1:1 showed 
good incorporation efficiency and high 
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percentage in vitro release of lansoprazole 
from micropellets. The range of particle size 
was between 327 to 431µm. 
Sato et al
43
 studied pharmacoscintigraphic 
evaluation of riboflavin containing 
microballons for floating drug delivery system 
in healthy human volunteers and found that 
microballons were very useful for improving 
drug bioavailability, resulting in more 
sustained pharmacologic action. 
Dave et al
44
 developed gastroretentive 
delivery system of ranitidine HCL. Guar gum, 
xanthan gum and HPMC were used as gel-
forming agents. Sodium carbonate was 
incorporated as a gas-generating agent. The 
effects of citric acids and stearic acid on drug 
release profile and floating properties were 
investigated. It was indicated that a low 
amount of citric acid and high amount of 
stearic acid favoured the sustained release of 
ranitidine HCL.  
Sato et al
45
 developed microballons (MB) by 
emulsion solvent diffusion method using 
enteric acrylic polymers dissolved in a mixture 
of dichloromethane and ethanol. The 
pharmacokinetics of riboflavin was 
investigated by urinary excretion. MB 
prepared by mixing with HPMC in varying 




 developed floating 
microspheres bearing acetohydroxamic acid 
using polycarbonates as drug carriers by 
emulsion (o/w) solvent evaporation 
techniques. The effect of polycarbonate 
concentration on morphology, particle size, 
entrapment efficiency and drug release rate 
was studied.  
El-Gibaly et al
47
 prepared floating 
microcapsules containing melatonin by the 
interaction of chitosan and a negatively 
charged surfactant, sodium dioctyl 
sulfosuccinate. The characteristics of the 
floating microcapsules generated compared 
well with the conventional non-floating 
microspheres. The data obtained suggest that 
the floating hollow microcapsules produced 
would be an interesting gastroretentive 
controlled release delivery system for drugs. 
Streubel et al
48
 developed and 
physiochemically characterized single-unit, 
floating controlled drug delivery system 
consisting of polypropylene foam powder and 
matrix-forming polymers. The highly porous 
foam powder provided low density and thus 




 developed floating 
microspheres of piroxicam capable of floating 
on simulated gastric and intestinal fluid. The 
microspheres were prepared by a solvent 
evaporation technique. Incorporation 
efficiency of over 95% was achieved and in 
vitro release of piroxicam from polycarbonate 
microspheres in simulated gastric fluid at 
37
O
C showed no significant  burst effect.  
Choi et al
50
 prepared floating beads from a 
sodium alginate solution containing CaCO3 or 
NaHCO3 as the gas-forming agent. The 
solution was dropped into 1 % CaCl2 solution 
containing 10% acetic acid for CO2 gas and 
gel formation. The effect of gas forming agent 
on bead size and floating properties were 
investigated.  The results of the study indicate 
that CaCO3 is superior to NaHCO3 as a gas-
forming agent in alginate bead preparation.  
El-Kamel et al
51
 prepared floating 
microparticles of ketoprofen by emulsion 
solvent diffusion technique. Four different 
ratios of Eudragit S 100 (ES) with Eudragit RL 
(ERL) were used. The drug retained in the 
floating microparticles decreased with 
increase in ERL content. The formulation 
containing 1:1 ratio of the above-mentioned 
polymers exhibited high percentage of floating 
particles in all the examined media. 
Formulation of “Floating Microspheres  / 
Micro Balloons” 
Hollow microspheres are prepared by solvent 
diffusion and evaporation methods to create 
the hollow inner core. The polymer is 
dissolved in an organic solvent and the drug is 
either dissolved or dispersed in the polymer 
solution. The solution containing the drug is 
then emulsified into an aqueous phase 
containing polyvinyl alcohol to form an oil-in-
water emulsion. After the formation of a stable 
emulsion, the organic solvent is evaporated 
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either by increasing the temperature under 
pressure or by continuous stirring. The solvent 
removal leads to polymer precipitation at the 
o/w interface of the droplets, forming the 
cavity and thus making them hollow to impart 
the floating properties. 
 
CONCLUSION 
Controlled release gastroretentive dosage 
forms (CR-GRDF) enable prolonged and 
continuous input of the drug to the upper parts 
of the gastrointestinal (GI) tract and improve 
the bioavailability of medications that are 
characterized by a narrow absorption window. 
CR-GRDF provides a means to utilize all the 
pharmacokinetic (PK) and pharmacodynamic 
(PD) advantages of controlled release dosage 
forms for such drugs. Based on the literature 
surveyed, it may be concluded that drug 
absorption in the gastrointestinal tract is a 
highly variable process and prolonging gastric 
retention of the dosage form extends the time 
for drug absorption. Thus gastroretentive 
dosage forms provide an additional advantage 
for drugs that are absorbed primarily in the 
upper segments of gastrointestinal tract, 
i.e.,stomach, duodenum and jejunum. Due to 
the complexity of pharmacokinetic and 
pharmacodynamic parameters, in vivo studies 
are required to establish the optimal dosage 
form for a specific drug. For a certain drug, 
interplay of its pharmacokinetic and 
pharmacodynamic parameters will determine 
the effectiveness and benefits of the CR-
GRDF compared to the other dosage forms. 
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